Latest Technology Companies News

Osteopore Limited reported a 6% increase in revenue to $1.56 million for the half-year ended June 2025, alongside a slight rise in net loss driven by expanded product development and compliance costs. The company secured key regulatory approvals and broadened its distribution footprint in Asia and the US.

NoviqTech Limited reported a $1.63 million loss for the half-year ending June 2025, while securing key partnerships and raising over $1 million to fuel its sustainability and blockchain innovation.

Adherium Limited reported a $12.68 million net loss for FY2025 as it pivots towards commercialising its smart inhaler technology in the US, supported by a $4.49 million capital raise.

Echo IQ Limited reported a sharp increase in losses for FY25 despite revenue growth, while securing FDA clearance and expanding its AI-driven cardiology platform across major US networks.

MedAdvisor Limited reported a staggering $60.2 million loss for FY25, driven by operational challenges and asset impairments, while divesting its ANZ business and becoming debt-free.

DorsaVi Limited reported a 13.9% revenue decline and a 21.7% rise in net loss for FY25, while securing over $3 million in capital to fuel new technology ventures.

Cluey Ltd has marked a pivotal year with a $4.4 million EBITDA improvement and its first positive operating cash flow quarter, alongside renewed student growth. The company is now pivoting towards AI-driven product expansion to sustain momentum.

Cluey Ltd reported a significantly reduced loss for FY25 alongside an 11% increase in new students and achieved positive operating cash flow in Q4, signaling progress in its path to profitability.

Hiremii Limited reported a near-flat revenue for FY2025 with a 25% increase in net loss, while pushing forward its AI-driven recruitment platform and completing a key acquisition to expand market reach.

Pure Hydrogen Corporation has raised A$1 million through a share placement with attaching options, aiming to accelerate its clean energy projects across Australia and the US.

Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.

Adveritas Limited reported a robust 89% increase in revenue to $7.84 million for FY25, driven by expanding customer contracts and product enhancements, while reducing its net loss by 39%. The company raised $8.5 million to fuel US expansion and new verticals.